Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Update on Gastrointestinal Stromal Tumors for Radiologists

  • Tirumani, Sree Harsha (Department of Imaging, Dana-Farber Cancer Institute) ;
  • Baheti, Akshay D. (Department of Radiology, Tata Memorial Centre) ;
  • Tirumani, Harika (Department of Radiology, University of Arkansas for Medical Sciences) ;
  • O'Neill, Ailbhe (Department of Imaging, Dana-Farber Cancer Institute) ;
  • Jagannathan, Jyothi P. (Department of Imaging, Dana-Farber Cancer Institute)
  • Received : 2016.08.10
  • Accepted : 2016.09.14
  • Published : 2017.01.01
⟨ Previous Next ⟩

Abstract

The management of gastrointestinal stromal tumors (GISTs) has evolved significantly in the last two decades due to better understanding of their biologic behavior as well as development of molecular targeted therapies. GISTs with exon 11 mutation respond to imatinib whereas GISTs with exon 9 or succinate dehydrogenase subunit mutations do not. Risk stratification models have enabled stratifying GISTs according to risk of recurrence and choosing patients who may benefit from adjuvant therapy. Assessing response to targeted therapies in GIST using conventional response criteria has several potential pitfalls leading to search for alternate response criteria based on changes in tumor attenuation, volume, metabolic and functional parameters. Surveillance of patients with GIST in the adjuvant setting is important for timely detection of recurrences.

Keywords

References

  1. Liegl B, Hornick JL, Lazar AJ. Contemporary pathology of gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009;23:49-68, vii-viii https://doi.org/10.1016/j.hoc.2008.12.002
  2. Call J, Walentas CD, Eickhoff JC, Scherzer N. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. BMC Cancer 2012;12:90 https://doi.org/10.1186/1471-2407-12-90
  3. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466-477 https://doi.org/10.1053/hupa.2002.124122
  4. Tirumani SH, Jagannathan JP, Krajewski KM, Shinagare AB, Jacene H, Ramaiya NH. Imatinib and beyond in gastrointestinal stromal tumors: a radiologist's perspective. AJR Am J Roentgenol 2013;201:801-810 https://doi.org/10.2214/AJR.12.10003
  5. Hornick JL, Fletcher CD. The significance of KIT (CD117) in gastrointestinal stromal tumors. Int J Surg Pathol 2004;12:93-97 https://doi.org/10.1177/106689690401200201
  6. Marrari A, Wagner AJ, Hornick JL. Predictors of response to targeted therapies for gastrointestinal stromal tumors. Arch Pathol Lab Med 2012;136:483-489 https://doi.org/10.5858/arpa.2011-0082-RA
  7. Gronchi A. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour. Eur J Cancer 2013;49:884-892 https://doi.org/10.1016/j.ejca.2012.10.025
  8. Wardelmann E, Buttner R, Merkelbach-Bruse S, Schildhaus HU. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 2007;451:743-749 https://doi.org/10.1007/s00428-007-0473-9
  9. Maleddu A, Pantaleo MA, Nannini M, Di Battista M, Saponara M, Lolli C, et al. Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (review). Oncol Rep 2009;21:1359-1366
  10. O'Regan KN, Shinagare AB, Saboo SS, Ramaiya NH, Jagannathan JP, Tirumani SH. Gastrointestinal stromal tumors (GIST): lesser known facts. Clin Imaging 2013;37:821-829 https://doi.org/10.1016/j.clinimag.2013.04.005
  11. Tirumani SH, Tirumani H, Jagannathan JP, Shinagare AB, Hornick JL, George S, et al. MDCT features of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumours. Br J Radiol 2014;87:20140476 https://doi.org/10.1259/bjr.20140476
  12. Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329-3337
  13. Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 2011;35:1712-1721 https://doi.org/10.1097/PAS.0b013e3182260752
  14. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010;28:1247-1253 https://doi.org/10.1200/JCO.2009.24.2099
  15. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349 https://doi.org/10.1200/JCO.2003.04.190
  16. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-5367 https://doi.org/10.1200/JCO.2008.17.4284
  17. Tirumani SH, Jagannathan JP, Hornick JL, Ramaiya NH. Resistance to treatment in gastrointestinal stromal tumours: what radiologists should know. Clin Radiol 2013;68:e429-e437 https://doi.org/10.1016/j.crad.2013.03.016
  18. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-4774 https://doi.org/10.1200/JCO.2006.06.2265
  19. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465 https://doi.org/10.1053/hupa.2002.123545
  20. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83 https://doi.org/10.1053/j.semdp.2006.09.001
  21. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008;39:1411-1419 https://doi.org/10.1016/j.humpath.2008.06.025
  22. Rutkowski P, Bylina E, Wozniak A, Nowecki ZI, Osuch C, Matlok M, et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011;37:890-896 https://doi.org/10.1016/j.ejso.2011.06.005
  23. Goh BK, Chow PK, Yap WM, Kesavan SM, Song IC, Paul PG, et al. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol 2008;15:2153-2163 https://doi.org/10.1245/s10434-008-9969-z
  24. Huang HY, Li CF, Huang WW, Hu TH, Lin CN, Uen YH, et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery 2007;141:748-756 https://doi.org/10.1016/j.surg.2007.01.024
  25. Gold JS, Gonen M, Gutierrez A, Broto JM, Garcia-del-Muro X, Smyrk TC, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009;10:1045-1052 https://doi.org/10.1016/S1470-2045(09)70242-6
  26. Chok AY, Goh BK, Koh YX, Lye WK, Allen JC Jr, Quek R, et al. Validation of the MSKCC gastrointestinal stromal tumor nomogram and comparison with other prognostication systems: single-institution experience with 289 patients. Ann Surg Oncol 2015;22:3597-3605 https://doi.org/10.1245/s10434-015-4400-z
  27. Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen SE, Brabec P, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012;13:265-274 https://doi.org/10.1016/S1470-2045(11)70299-6
  28. O'Neill AC, Shinagare AB, Kurra V, Tirumani SH, Jagannathan JP, Baheti AD, et al. Assessment of metastatic risk of gastric GIST based on treatment-naive CT features. Eur J Surg Oncol 2016;42:1222-1228 https://doi.org/10.1016/j.ejso.2016.03.032
  29. Tirumani SH, Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH, Raut CP. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection. Eur J Surg Oncol 2014;40:420-428 https://doi.org/10.1016/j.ejso.2013.10.021
  30. NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma Version 2. 2016. NCCN. Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed March 31, 2016
  31. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307:1265-1272 https://doi.org/10.1001/jama.2012.347
  32. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480 https://doi.org/10.1056/NEJMoa020461
  33. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338 https://doi.org/10.1016/S0140-6736(06)69446-4
  34. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295-302 https://doi.org/10.1016/S0140-6736(12)61857-1
  35. Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013;14:1175-1182 https://doi.org/10.1016/S1470-2045(13)70453-4
  36. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004;183:1619-1628 https://doi.org/10.2214/ajr.183.6.01831619
  37. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-1759 https://doi.org/10.1200/JCO.2006.07.3049
  38. Rezai P, Pisaneschi MJ, Feng C, Yaghmai V. A radiologist's guide to treatment response criteria in oncologic imaging: anatomic imaging biomarkers. AJR Am J Roentgenol 2013;201:237-245 https://doi.org/10.2214/AJR.12.9862
  39. Tirumani SH, Shinagare AB, O'Neill AC, Nishino M, Rosenthal MH, Ramaiya NH. Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients. Eur Radiol 2016;26:286-295 https://doi.org/10.1007/s00330-015-3829-6
  40. Schiavon G, Ruggiero A, Bekers DJ, Barry PA, Sleijfer S, Kloth J, et al. The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. Eur J Cancer 2014;50:972-980 https://doi.org/10.1016/j.ejca.2014.01.004
  41. Schiavon G, Ruggiero A, Schoffski P, van der Holt B, Bekers DJ, Eechoute K, et al. Tumor volume as an alternative response measurement for imatinib treated GIST patients. PLoS One 2012;7:e48372 https://doi.org/10.1371/journal.pone.0048372
  42. Schramm N, Englhart E, Schlemmer M, Hittinger M, Ubleis C, Becker CR, et al. Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria. Eur J Radiol 2013;82:951-958 https://doi.org/10.1016/j.ejrad.2013.02.034
  43. Shinagare AB, Barysauskas CM, Braschi-Amirfarzan M, O'Neill AC, Catalano PJ, George S, et al. Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors. Clin Imaging 2016;40:880-884 https://doi.org/10.1016/j.clinimag.2016.04.007
  44. Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, et al. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. Eur J Cancer 2014;50:981-986 https://doi.org/10.1016/j.ejca.2013.11.037
  45. Van den Abbeele AD, Badawi RD, Tetrault RJ, Cliche JP, Manola J, Spangler T, et al. FDG-PET as a surrogate marker for response to Gleevec (TM) (imatinib mesylate) in patients with advanced gastrointestinal stromal tumors (GIST). J Nucl Med 2003;44:24-25
  46. Van den Abbeele AD for the GIST Collaborative PET Study Group. F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST) [abstract]. Proc Am Soc Clin Oncol 2001;20:362a
  47. Van den Abbeele AD. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist 2008;13 Suppl 2:8-13 https://doi.org/10.1634/theoncologist.13-S2-8
  48. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7:vii49-vii55 https://doi.org/10.1093/annonc/mds088
  49. Meyer M, Hohenberger P, Apfaltrer P, Henzler T, Dinter DJ, Schoenberg SO, et al. CT-based response assessment of advanced gastrointestinal stromal tumor: dual energy CT provides a more predictive imaging biomarker of clinical benefit than RECIST or Choi criteria. Eur J Radiol 2013;82:923-928 https://doi.org/10.1016/j.ejrad.2013.01.006
  50. Betz M, Kopp HG, Spira D, Claussen CD, Horger M. The benefit of using CT-perfusion imaging for reliable response monitoring in patients with gastrointestinal stromal tumor (GIST) undergoing treatment with novel targeted agents. Acta Radiol 2013;54:711-721 https://doi.org/10.1177/0284185113484642
  51. Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005;235:892-898 https://doi.org/10.1148/radiol.2353040332
  52. Joensuu H, Reichardt P, Eriksson M, Sundby Hall K, Vehtari A. Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients. Radiology 2014;271:96-103 https://doi.org/10.1148/radiol.13131040

Cited by

  1. Association between CT imaging features and KIT mutations in small intestinal gastrointestinal stromal tumors vol.9, pp.None, 2017, https://doi.org/10.1038/s41598-019-43659-9
  2. Gastrointestinal Stromal Tumor (GIST) from esophagus to anorectum - diagnosis, response evaluation and surveillance on computed tomography (CT) scan vol.29, pp.2, 2019, https://doi.org/10.4103/ijri.ijri_354_18
  3. Gastrointestinal stromal tumor risk classification: spectral CT quantitative parameters vol.44, pp.7, 2017, https://doi.org/10.1007/s00261-019-01973-w
  4. Risk stratification in GIST: shape quantification with CT is a predictive factor vol.30, pp.4, 2020, https://doi.org/10.1007/s00330-019-06561-6
  5. Comprehensive Review of Abdominopelvic Mesenchymal Tumors With Radiologic Pathologic Correlation and Update on Current Treatment Guidelines—Part 2 vol.41, pp.2, 2020, https://doi.org/10.1053/j.sult.2020.03.003
  6. Computed tomography-based radiomics model for discriminating the risk stratification of gastrointestinal stromal tumors vol.125, pp.5, 2017, https://doi.org/10.1007/s11547-020-01138-6
  7. Decoding Genes: Current Update on Radiogenomics of Select Abdominal Malignancies vol.40, pp.6, 2017, https://doi.org/10.1148/rg.2020200042
  8. Identifying Small Bowel Gastrointestinal Stromal Tumor as the Culprit Lesion in Obscure Gastrointestinal Bleeding: Emphasis on Angiographic Findings vol.82, pp.None, 2021, https://doi.org/10.3348/jksr.2021.0029
  9. Gastrointestinal Stromal Tumors-A Mini Review vol.11, pp.8, 2021, https://doi.org/10.3390/jpm11080694
  10. Clinicopathological characteristics and prognosis of gastrointestinal stromal tumors containing air-fluid levels vol.16, pp.12, 2021, https://doi.org/10.1371/journal.pone.0261566